TAK / Phathom Pharmaceuticals: Undiscovered Gem

Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q2 2023 Earnings Conference Call October 26, 2023 6:00 AM ET Company Participants Christopher O'Reil more_horizontal

Japan's biggest drugmaker Takeda Pharmaceutical on Thursday slashed its full-year profit forecast by 36% as it contends with disappointments in its de more_horizontal

High yields may seem attractive, however, homework can go a long way. Takeda's Phase 3 ADMIRE CD II study & Phase 3 EXCLAIM-2 trial both failed to mee more_horizontal

Takeda 4502, -0.33% said Tuesday its trial of darvadstrocel in the treatment of complex Crohn's Perianal Fistulas didn't meet its primary endpoint bas more_horizontal

American depositary receipts of Takeda Pharmaceutical Co. 4502, -1.79% TAK, -2.16% rose more than 1% in the extended session Tuesday after the Japan-b more_horizontal

Takeda Pharmaceutical said on Monday it would be working with the U.S. health regulator towards a voluntary withdrawal of its lung cancer therapy in t more_horizontal

Drugmakers have begun shipping copycat versions of Takeda Pharmaceutical's drug Vyvanse, which is expected to offset the ongoing shortage of the ADHD more_horizontal

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Neverthe more_horizontal